Latest news with #KidneyVault™PortableRenalPerfusionSystem
Yahoo
21-04-2025
- Business
- Yahoo
Paragonix Celebrates 100th Kidney Transplant Case with FDA-Cleared KidneyVault™ System
Tennessee Donor Services utilizes Paragonix KidneyVault™ Renal Perfusion System in milestone case. WALTHAM, Mass., April 21, 2025--(BUSINESS WIRE)--Paragonix Technologies, a leader in organ transplant technologies and services, today announced the successful completion of its hundredth case using the FDA-cleared KidneyVault™ Portable Renal Perfusion System. This milestone was achieved with the support of Tennessee Donor Services (TDS), an Organ Procurement Organization (OPO) that serves more than 6 million people across Tennessee and Virginia. In recent years, the transplantation industry has removed geographic barriers to ensure organs may reach those in greatest need, meaning organs now travel farther and remain outside the body longer. For kidney transport, the gold standard of preservation is hypothermic machine perfusion - a clinically accepted therapy that continuously pumps a specialized solution through the organ. The KidneyVault System is the first hypothermic machine perfusion device specifically designed to maximize mobility. The device offers a comprehensive, portable solution from end-to-end, allowing transplant teams to continuously perfuse the kidney and monitor key perfusion metrics in real-time through a mobile-friendly, data-driven dashboard. The innovative system was first used shortly after achieving FDA clearance in late 2024 and has been rapidly adopted by likeminded organizations across the nation ever since. Now, over 12 OPOs stock the device, and 100 donor kidneys have been placed in a KidneyVault for transplant. This rapid adoption reflects a broader shift in the field — one that embraces new technology to meet the evolving demands of organ recovery and allocation. "Tennessee Donor Services' mission is to save and improve lives through organ, eye, and tissue donation, and we're proud of our teams who embrace innovation to save as many lives as possible. It's exciting to partner with Paragonix to be an early adopter of the KidneyVault, a technology that will help more people get their lifesaving transplant, and work alongside their teams to make donation and transplant possible," said Jill Grandas, CEO of Tennessee Donor Services. Leading OPOs like Tennessee Donor Services are leveraging the KidneyVault System to expand access to the limited supply of donor organs and improve post-transplant outcomes. As of April 2025, nearly 90,700 people are on the kidney transplant waiting list in the U.S., representing 86% of the national transplant list. In 2024, 27,761 kidney transplants were performed, highlighting the urgent need for innovative solutions to address the organ shortage. "This hundredth KidneyVault case is a significant milestone for Paragonix and underscores our company's commitment to enhancing the future of organ transplantation," said Dr. Lisa Anderson, President of Paragonix Technologies. "We are proud to offer advanced preservation technologies across all solid organ transplants, and our ability to provide a truly portable renal perfusion system aligns with our mission to provide 'Every Possible Advantage' to those waiting for lifesaving transplants." For more information about Paragonix Technologies, please visit About Tennessee Donor Services An Extraordinary Commitment to Science, Health, and Hope Tennessee Donor Services is a non-profit, organ procurement organization (OPO) dedicated to saving and improving lives by connecting organ and tissue donations to the patients who need them. TDS serves more than six million people in Tennessee and Virginia. About Paragonix Technologies Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation. A Getinge company, Paragonix Technologies provides Advanced Organ Preservation ("AOP") devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit Connect with us on LinkedIn: Paragonix Technologies Follow us on Twitter: @ParagonixSherpa Like Us on Facebook: Paragonix SherpaPak View source version on Contacts Media: Adam LafreniereVice President, Marketingmarketing@
Business Wire
21-04-2025
- Health
- Business Wire
Paragonix Celebrates 100 th Kidney Transplant Case with FDA-Cleared KidneyVault™ System
WALTHAM, Mass.--(BUSINESS WIRE)-- Paragonix Technologies, a leader in organ transplant technologies and services, today announced the successful completion of its hundredth case using the FDA-cleared KidneyVault™ Portable Renal Perfusion System. This milestone was achieved with the support of Tennessee Donor Services (TDS), an Organ Procurement Organization (OPO) that serves more than 6 million people across Tennessee and Virginia. In recent years, the transplantation industry has removed geographic barriers to ensure organs may reach those in greatest need, meaning organs now travel farther and remain outside the body longer. For kidney transport, the gold standard of preservation is hypothermic machine perfusion - a clinically accepted therapy that continuously pumps a specialized solution through the organ. The KidneyVault System is the first hypothermic machine perfusion device specifically designed to maximize mobility. The device offers a comprehensive, portable solution from end-to-end, allowing transplant teams to continuously perfuse the kidney and monitor key perfusion metrics in real-time through a mobile-friendly, data-driven dashboard. The innovative system was first used shortly after achieving FDA clearance in late 2024 and has been rapidly adopted by likeminded organizations across the nation ever since. Now, over 12 OPOs stock the device, and 100 donor kidneys have been placed in a KidneyVault for transplant. This rapid adoption reflects a broader shift in the field — one that embraces new technology to meet the evolving demands of organ recovery and allocation. 'Tennessee Donor Services' mission is to save and improve lives through organ, eye, and tissue donation, and we're proud of our teams who embrace innovation to save as many lives as possible. It's exciting to partner with Paragonix to be an early adopter of the KidneyVault, a technology that will help more people get their lifesaving transplant, and work alongside their teams to make donation and transplant possible,' said Jill Grandas, CEO of Tennessee Donor Services. Leading OPOs like Tennessee Donor Services are leveraging the KidneyVault System to expand access to the limited supply of donor organs and improve post-transplant outcomes. As of April 2025, nearly 90,700 people are on the kidney transplant waiting list in the U.S., representing 86% of the national transplant list. In 2024, 27,761 kidney transplants were performed, highlighting the urgent need for innovative solutions to address the organ shortage. "This hundredth KidneyVault case is a significant milestone for Paragonix and underscores our company's commitment to enhancing the future of organ transplantation," said Dr. Lisa Anderson, President of Paragonix Technologies. 'We are proud to offer advanced preservation technologies across all solid organ transplants, and our ability to provide a truly portable renal perfusion system aligns with our mission to provide ' Every Possible Advantage' to those waiting for lifesaving transplants.' For more information about Paragonix Technologies, please visit About Tennessee Donor Services An Extraordinary Commitment to Science, Health, and Hope Tennessee Donor Services is a non-profit, organ procurement organization (OPO) dedicated to saving and improving lives by connecting organ and tissue donations to the patients who need them. TDS serves more than six million people in Tennessee and Virginia. About Paragonix Technologies Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation. A Getinge company, Paragonix Technologies provides Advanced Organ Preservation ('AOP') devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit
Yahoo
28-01-2025
- Health
- Yahoo
Paragonix Announces World's First-In-Human Use of KidneyVault Renal Perfusion System
Novel portable hypothermic perfusion technology facilitates the preservation and transport of perfused donor kidneys throughout journey from donor to recipient WALTHAM, Mass., January 28, 2025--(BUSINESS WIRE)--Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today the completion of the world's first-in-human cases utilizing its FDA-cleared KidneyVault™ Portable Renal Perfusion System, marking a new chapter in kidney transplant preservation. These landmark cases included the successful transport of four donor kidneys to four separate medical institutions across the nation in a 24-hour period last December. The successful transplants were made possible through the support of leading OPOs (organ procurement organizations), including LifeGift of Houston, Texas. The KidneyVault Portable Renal Perfusion System received FDA clearance in October of 2024. The lightweight device is designed for convenient end-to-end hypothermic perfusion, offering new levels of standardization that aligns with kidney allocation workflow of all involved parties. OPOs and transplant centers can remotely monitor the device in real-time with a data-driven dashboard that shares perfusion parameters, temperature conditions, and other critical data at all times. The combination of portable perfusion technology and real-time data insights offer OPOs and transplant centers a comprehensive solution currently unavailable on the market. OPOs like LifeGift leverage advanced technologies such as the KidneyVault System to improve post-transplant outcomes and increase national access to the limited pool of available donations. Kidney donation represents a striking demand of nearly 90,000 total individuals listed in need of a donation – 86% of the 2024 transplant waiting list. At the end of November 2024, just over 25,000 kidney transplantations were able to be performed. "Hypothermic perfusion increases the availability of high-quality donor kidneys nationwide," said Yolanda Becker, MD, Vice President and Chief Medical Officer at LifeGift. "However, historically, it was not always feasible to deliver every kidney on pump due to the distances traveled increasing cold ischemic times. LifeGift is now at the forefront of portable perfusion technologies that allow us to transport kidneys greater distances, by ground or commercial air, using a single controlled device from end-to-end. This hands-off solution provides the flexibility to deliver a kidney on pump to transplant centers." The national kidney allocation policy was revised in recent years to enable broader organ distribution strategies and increase the overall volume of transplant offers. Placement efforts have increased dramatically for each kidney, resulting in more complex logistics and extended transport times in which the kidney remains outside of the body, a concept known as cold ischemia time. Notably, the clinical community has come to rely on hypothermic machine perfusion devices to compensate for longer cold ischemia times by pumping a perfusate solution through the kidney to sustain viability in a controlled environment. "LifeGift is proud to be among the first to adopt this innovative technology," said Kevin A. Myer, MSHA, LifeGift President & CEO. "LifeGift is committed to clinical research and new technologies that will help save lives today and in the future. The device allows us to provide our transplant center partners with recovered kidneys that have been monitored throughout the journey, regardless of the transportation mode. The portability of the system will facilitate broader sharing of machine-perfused kidneys and will result in greater use of recovered kidneys for transplant." The successful first-in-human use of the KidneyVault System marks a major milestone in Paragonix Technologies' mission to transform the standard of care in transplantation. Notably, Paragonix now offers advanced preservation technologies across all solid organ transplantation – a world first. "We are fully committed to ensuring every patient has the best possible chance at life," said Lisa Anderson, PhD, President of Paragonix Technologies. "This achievement highlights the potential of this one-of-a kind portable perfusion technology and sets a new standard for safety, reliability, and efficiency." For more information about Paragonix Advanced Organ Preservation devices, please visit About LifeGift LifeGift is a nonprofit, 501(c)(3) health services organization. As the organ procurement organization (OPO) for North, Southeast and West Texas, we partner with more than 200 hospitals across 109 counties to save and heal lives. LifeGift is a founding member of Donate Life Texas, the organization that manages the organ, eye and tissue donor registry. For more information, please visit About Paragonix Technologies Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation. Paragonix Technologies provides Advanced Organ Preservation ("AOP") devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit Follow us on Twitter: @ParagonixSherpa Connect with us on LinkedIn: Paragonix Technologies Like Us on Facebook: Paragonix Technologies View source version on Contacts Paragonix Media Contact: Adam Lafreniere, Vice President, Marketingmarketing@ Sign in to access your portfolio
